Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Substrate Specificity of Clostridial Glucosylating Toxins and Their Function on Colonocytes Analyzed by Proteomics Techniques

(2013) Johannes Zeiser et al.   JOURNAL OF PROTEOME RESEARCH

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations

(2012) Klaus Rehe et al.   EMBO Molecular Medicine

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression

(2012) S Bomken et al.   LEUKEMIA

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

(2012) H Pfeifer et al.   LEUKEMIA

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative G

(2011) Susana Rives et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia

(2011) Loren D. Walensky   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

(2010) F. Ravandi et al.   BLOOD

Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00

(2010) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR–ABL-positive acute lymphoblastic leukemia

(2010) S Mizuta et al.   LEUKEMIA

mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets

(2009) William Ritchie et al.   BIOINFORMATICS

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993

(2009) Adele K. Fielding et al.   BLOOD

Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas

(2009) P. Mu et al.   GENES & DEVELOPMENT

miR-19 is a key oncogenic component of mir-17-92

(2009) V. Olive et al.   GENES & DEVELOPMENT

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

(2009) J.-M. Ribera et al.   HAEMATOLOGICA

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2009) Kirk R. Schultz et al.   JOURNAL OF CLINICAL ONCOLOGY

miR-24 Inhibits Cell Proliferation by Targeting E2F2, MYC, and Other Cell-Cycle Genes via Binding to “Seedless” 3′UTR MicroRNA Recognition Elements

(2009) Ashish Lal et al.   MOLECULAR CELL

E2F1-Regulated MicroRNAs Impair TGFβ-Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer

(2008) Fabio Petrocca et al.   CANCER CELL

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters

(2008) Andrea Ventura et al.   CELL

Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes

(2008) Changchun Xiao et al.   NATURE IMMUNOLOGY

mirWIP: microRNA target prediction based on microRNA-containing ribonucleoprotein–enriched transcripts

(2008) Molly Hammell et al.   NATURE METHODS